Measles medical therapy: Difference between revisions
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{JS}} | {{CMG}}; {{AE}} {{JS}} | ||
==Overview== | ==Overview== | ||
Despite the efforts made in the past years to develop a treatment regimen for measles, there is still no specific antiviral therapy for measles virus, however, some drugs such as ribavirin and interferon-α have been used in the more severe cases of the condition.<ref name="MossGriffin2012">{{cite journal|last1=Moss|first1=William J|last2=Griffin|first2=Diane E|title=Measles|journal=The Lancet|volume=379|issue=9811|year=2012|pages=153–164|issn=01406736|doi=10.1016/S0140-6736(10)62352-5}}</ref> | |||
There is no specific treatment or antiviral therapy for uncomplicated measles. Most patients with uncomplicated measles will recover with rest and supportive treatment. | There is no specific treatment or antiviral therapy for uncomplicated measles. Most patients with uncomplicated measles will recover with rest and supportive treatment. | ||
Revision as of 14:56, 24 June 2014
|
Measles Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Measles medical therapy On the Web |
|
American Roentgen Ray Society Images of Measles medical therapy |
|
Risk calculators and risk factors for Measles medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Despite the efforts made in the past years to develop a treatment regimen for measles, there is still no specific antiviral therapy for measles virus, however, some drugs such as ribavirin and interferon-α have been used in the more severe cases of the condition.[1]
There is no specific treatment or antiviral therapy for uncomplicated measles. Most patients with uncomplicated measles will recover with rest and supportive treatment.
Medical Therapy
References
- ↑ Moss, William J; Griffin, Diane E (2012). "Measles". The Lancet. 379 (9811): 153–164. doi:10.1016/S0140-6736(10)62352-5. ISSN 0140-6736.